Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 6/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.43 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2359095 | 0.87 | NR4A2 (0.41) | NR4A2CFTRMAP2K1PDK2 | |
| SCHEMBL2541630 | 0.86 | F7 (0.43) | NR4A2TMPRSS4TP53MAPTRAB9A | |
| SCHEMBL2024463 | 0.83 | NR4A2 (0.47) | NR4A2CFTRMAPTSMN1; SMN2MAP2K1 | |
| SCHEMBL29575721 | 0.83 | NR4A2 (0.47) | NR4A2CFTRMAPTSMN1; SMN2MAP2K1 | |
| SCHEMBL2546812 | 0.77 | NR4A2 (0.45) | NR4A2SMN1; SMN2HTTLMNAMAP2K1 | |
| SCHEMBL2798818 | 0.76 | ABL1 (0.58) | NR4A2MRGPRX4TMPRSS4ABL1CFTR | |
| SCHEMBL4365379 | 0.76 | ABL1 (0.54) | NR4A2MRGPRX4TMPRSS4ABL1CFTR | |
| SCHEMBL2359387 | 0.73 | EIF4E (0.41) | MRGPRX4LMNA | |
| SCHEMBL16549389 | 0.71 | KDM4E (0.56) | MAPTPDK2 | |
| SCHEMBL1155039 | 0.70 | NR4A2 (0.50) | NR4A2RAB9ASMN1; SMN2HTTMAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349997-B1 | ATROPISOMERS OF (HYDROXYALKYL) PYRROLE DERIVATIVES | EXELIXIS INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2349997-B1 | ATROPISOMERS OF (HYDROXYALKYL) PYRROLE DERIVATIVES | EXELIXIS INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8487117-B2 | Atropisomers of (hydroxyalkyl) pyrrole derivatives | EXELIXIS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487117-B2 | Atropisomers of (hydroxyalkyl) pyrrole derivatives | EXELIXIS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487117-B2 | Atropisomers of (hydroxyalkyl) pyrrole derivatives | EXELIXIS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110263673-A1 | Atropisomers of (Hydroxyalkyl) Pyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263673-A1 | Atropisomers of (Hydroxyalkyl) Pyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2349997-A1 | ATROPISOMERS OF (HYDROXYALKYL) PYRROLE DERIVATIVES | Exelixis, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010042622-A1 | ATROPISOMERS OF (HYDROXYALKYL) PYRROLE DERIVATIVES | EXELIXIS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263673-A1 | Atropisomers of (Hydroxyalkyl) Pyrrole Derivatives | ADRB3, HSD11B1, AKR1C3 | NR4A2 711/4885MRGPRX4 2935/4885TMPRSS4 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.